ORIC PHARMACEUTICALS, INC. Total Liabilities and Equity
ORIC PHARMACEUTICALS, INC. (ORIC) had Total Liabilities and Equity of $404.69 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-03
- 2026-06-30: Liabilities and Equity $404.69M.
- 2026-03-31: Liabilities and Equity $436.76M.
- 2025-12-31: Liabilities and Equity $408.89M.
- 2025-09-30: Liabilities and Equity $431.19M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $404.69M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $436.76M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $408.89M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $431.19M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $346.86M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $242.86M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $274.14M 10-K · filed 2026-02-23 |
| 2024-09-30 | $302.07M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $328.91M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $350.79M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $252.01M 10-K · filed 2025-02-18 |
| 2023-09-30 | $274.33M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $291.82M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $226.65M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $247.18M 10-K · filed 2024-03-11 |
| 2022-09-30 | $238.00M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $259.68M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $275.06M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $298.64M 10-K · filed 2023-03-16 |
| 2021-09-30 | $314.18M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $268.23M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $283.96M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $299.00M 10-K · filed 2022-03-21 |
| 2020-09-30 | $191.66M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $201.53M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $85.06M 10-Q · filed 2020-05-20 |
| 2019-12-31 | $94.09M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |